The largest database of trusted experimental protocols

13 protocols using anti pd 1 pe cy7

1

Phenotypic Analysis of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fresh PBMCs from patients and healthy donors were washed and stained with the following antibodies at 4 °C for 15 min: anti-CD3-V450 (#560366, BD Biosciences), anti-CD4-V500 (#560769, BD Biosciences), anti-CD45RA-PE-Cy7 (#560675, BD Biosciences), anti-CXCR5-APC (#356907, BioLegend), and anti-PD-1-PE-Cy7 (#561272, BD Biosciences). For intracellular staining of anti-Foxp3-Alexa Fluor 488 (#560047, BD Biosciences), the cells were fixed and permeabilized with Transcription Factor Buffer at 4 °C for 30 min and were washed with Perm/Wash Buffer (BD Biosciences) before intracellular staining. Isotype-matched control antibodies were used to monitor the background. The well-stained cells were subjected to flow cytometry using a BD FACSLyric system and were further analyzed using the FlowJo v10 software (TOMY Digital Biology).
+ Open protocol
+ Expand
2

Tetramer-Based Enrichment of Antigen-Specific T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs (2.4–10 × 106) were stained with WT HLA-A2S269–277-PE and variant HLA-A2S269–277-APC tetramers at room temperature for 1 h in MACS buffer (PBS with 0.5% BSA and 2 mM EDTA). Cells were then incubated with anti-PE and anti-APC microbeads (Miltenyi Biotec), and tetramer+ cells were enriched using magnetic separation (9 (link)). Lymphocytes were stained with anti-CD71-BV421 (#562995), anti-CD4-BV650 (#563875), anti-CD27-BV711 (#563167), anti-CD38-BV786 (#563964), anti-CCR7-AF700 (#561143), anti-CD14-APC-H7 (#560180), anti-CD19-APC-H7 (#560177), anti-CD45RA-FITC (#555488), anti-CD8-PerCP-Cy5.5 (#565310), anti-CD95-PE-CF594 (#562395), anti-PD1-PE-Cy7 (#561272) (BD Biosciences), anti-CD3-BV510 (#317332), anti-HLA-DR-BV605 (#307640) (BioLegend), and LIVE/DEAD near-infrared stain (#L10119, Invitrogen) for 30 min, fixed with 1% PFA before acquiring data on an LSRII Fortessa (BD Bioscience). FCS files were analyzed using FlowJo v10 software.
+ Open protocol
+ Expand
3

Multiparametric Flow Cytometry Immunophenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were mechanically homogenized, followed by staining for surface molecules using LIVE/DEAD fixable Aqua (Invitrogen, 1:1000 dilution) and anti-CD4 PE-Cy5 (RPA-T4, BD, 1:50 dilution), anti-CD3 PE-Cy7 (UCHT1, eBioscience, 1:50 dilution), anti-CD45RA V450 (H100, eBioscience, 1:100 dilution), anti-CXCR5 conjugated with Alexa Fluor 488 (RF8B2, eBioscience, 1:50 dilution), Alexa Fluor 647 (RF8B2, BD, 1:50 dilution), or biotin (RF8B2, BD Biosciencese, 1:50 dilution)/streptavidin APC-Cy7 (1:400 dilution), anti-PSGL-1 PE (KPL-1, BD, 1:50 dilution) or APC (FLEG, eBioscience, 1:50 dilution), anti-ICOS FITC (C398.4A, eBioscience, 1:50 dilution), anti-CCR7 FITC (150503, R&D Systems, 1:50 dilution), anti-CD62L FITC (DREG56, eBioscience, 1:50 dilution), anti-CXCR4 PE-Cy5 (12G5, eBioscience, 1:50 dilution), anti-CD200 APC (OX104, eBioscience, 1:50 dilution), anti-OX40 PE-Cy5 (ACT35, BD, 1:50 dilution), anti-PD-1 PE-Cy7 (EH12.1, BD, 1:50 dilution), anti-CXCR3 BV421(1C6/CXCR3, BD, 1:50), anti-IL-2RA PE (M-A251, BD, 1:25), anti-CD19 APC-Cy7 (SJ25C1, eBioscience, 1:50 dilution), anti-IgD PE-Cy7 (IA6-2, BD, 1:50 dilution), anti-CD38 V450 (HIT2, BD, 1:50 dilution), and anti-IL-10R PE (3F9, Biolegend, 1:50 dilution).
+ Open protocol
+ Expand
4

Nivolumab Blockade of PD1 Expression on T-cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
PD1 expression on T-cells was blocked by incubating with 20 µg/mL Nivolumab (anti-PD1, MedChemExpress, NJ, USA) for 30 min at 37 °C. After incubation, cells were washed twice with PBSx1 supplemented with 0.5% BSA and 0.1% sodium azide, then washed once with PBSx1 before being centrifuged at 1500 rpm for 5 min. Next, cells were incubated with Fc Block (Milteny Biotech, Bergisch Gladbach, Alemania) for 30 min at 4 °C and then washed with PBSx1 supplemented with 0.5% BSA and 0.1% sodium azide before being centrifuged at 1500 rpm for 5 min. The cells were then subjected to surface staining using anti-Nivolumab PE (Anti-Human IgG4 pFc, Abcam, Cambridge, United Kingdom), anti-PD1 PE-Cy7 (Clone: EH12.1, BD Pharmingen, San Jose, CA, USA), and CD3 PERCP (Clone: HIT3a, BD Pharmingen) [27 (link)]. The corresponding isotypes and tube with cells without previous Nivolumab incubation were used as controls. PD1 expression and Nivolumab binding through human IgG4 were evaluated by flow cytometry using FACSCanto II (BD Biosciences) and analyzed using FlowJo (Tree Star, Ashland, OR, USA).
+ Open protocol
+ Expand
5

Phenotyping Immune Cells in NOD Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Thymocytes and peripheral T lymphocyte subsets from NOD, with or without MK626 treatment, were stained using an optimized panel of fluorochrome-conjugated monoclonal antibodies (mAb) (shown in Table 1). Specifically for T cell regulatory subset, T cells from spleen and PLNs were stained with anti-CD4-APCCy5.5 (BD), anti-CD25-PerCP (BD) and anti-FoxP3-eF450 (EBiosciences). Also T cells were stained with anti-CD8-V500 (BD), anti-PD1-PeCy7 (BD) and anti-CD122-biotin (BD). SA-APC (BD) was used as a secondary antibody. Analyses were run on a FACS Canto II flow cytometer (BD).
+ Open protocol
+ Expand
6

Multiparameter Flow Cytometry Analysis of T Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
EDTA-treated whole blood (50 μL) was stained with 20 μL of BD Multitest 6-color TBNK reagent in Trucount tubes (BD Biosciences. San Jose, CA, USA) for 15 min. After lysis of red blood cells, T, B and NK lymphocyte subsets were enumerated with a FACSCanto II flow cytometer, and data were analyzed using FACSDiva software (BD Biosciences) [55 (link)].
For the analysis of T helper cell subsets after vaccination, EDTA-treated whole blood was incubated with: anti-CD3-PerCPy5.5 and anti-CD4-KO (Beckman Coulter); anti-CXCR3-PE, anti-CCR6-PB and anti-PD-1-PECy7 (BD Biosciences). Acquisition was performed with a Navios flow cytometer (Beckman Coulter), and data were analyzed with FlowJo software v10.6.2. Th1 cells were defined as CD4+CXCR3+CCR6-, Th2 cells as CD4+CXCR3-CCR6- and Th17 cells as CD4+CXCR3-CCR6+. PD-1 was considered as a recent activation marker.
+ Open protocol
+ Expand
7

Multi-phenotypic Profiling of T Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lymphocytes from human thymi, cord blood, lymph nodes (mesenteric and pancreatic), spleen and blood samples were cell surface stained with anti‐CD3‐AF700 (557943)/anti‐CD3‐PE‐CF594 (562280), anti‐CD19‐BV570 (BioLegend, San Diego, CA, USA; 302236), anti‐CD4‐APC‐H7 (560158)/anti‐CD4‐BV650 (563875), anti‐CD8‐BV421 (BioLegend, 301035)/anti‐CD8‐BV650 (563875)/anti‐CD8‐PerCP‐Cy5.5 (565310), anti‐CD27‐BV711 (563167), anti‐CD45RA‐FITC (555488), anti‐PD‐1‐PE‐Cy7 (561272) antibodies (all from BD Biosciences, San Jose, CA, USA), unless otherwise stated with their catalogue number in brackets) and LIVE/DEAD (Aqua, Near‐IR, Molecular Probes, Eugene, OR, USA) or 7‐amino‐actinomycin D (Sigma‐Aldrich, Darmstadt, Germany) on ice for 30 min in PBS. Human PBMCs were sorted for CD27+CD45RA+ naïve or CD27+CD45RA TCM CD4+ and CD8+ T cell populations using FACS Aria III (BD Biosciences). Alternatively, cells were fixed and permeablized using the eBioscience Foxp3 staining kit (ThermoFisher Scientific, Waltham, MA, USA) then intracellularly stained with anti‐SATB1‐AF647 (BD Biosciences, 562378) and anti‐GzmB‐AF700 (BD Biosciences, 560213). Samples were acquired using a BD LSR Fortessa (BD Bioscience) and analyzed using FlowJo software (V10.4.2 and 10.5, Treestar, Ashland, OR, USA) and GraphPad Prism (GraphPad Software, La Jolla, CA, USA, V7.02).
+ Open protocol
+ Expand
8

Multiparametric Flow Cytometric Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells were incubated with a mix of monoclonal antibodies consisting of anti-CD3 APC (BioLegend, San Diego, USA; cat. No. 300439, clone: UCHT1), anti-TCRγδ BV421 (BD Biosciences, Warsaw, Poland; cat. No. 744870, clone: 11F2), anti-Vδ1 FITC (ThermoFisher, Warsaw, Poland; cat. No. TCR2730, clone: TS8.2), anti-Vδ2 PE (BioLegend; cat. No. 331408, clone: B6), anti-CTLA-4 APC-Fire750 (BioLegend; cat. No. 349930, clone: L3D10), anti-PD-1 PE-Cy7 (BD Biosciences, Franklin Lakes, USA; cat. No. 561272, clone: EH12.1), anti-TIGIT BV650 (BD Biosciences; cat. No. 747840, clone: 741182), anti-NKp30 BV785 (BioLegend; cat No. 325230, clone: P30-15), and anti-CD226 BV605 (BD Biosciences; cat. No. 742495, clone: DX11). Fluorescence minus one (FMO) controls were used to set the correct gates for each fluorophore. Samples were acquired on a Cytoflex LX (Beckman Coulter, Warsaw, Poland) and analyzed with FlowJo 10 (BD Biosciences). The percentage of positive cells was a standard measure for each of the markers except for CD226, where mean fluorescence intensity (MFI) was additionally provided due to its high overall expression.
+ Open protocol
+ Expand
9

Flow Cytometry Analysis of Intracellular Notch1

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole blood was permeabilized and fixed using cytofix/cytoperm (BD Pharmingen, San Jose, CA, USA) according to manufacturer’s protocol followed by staining for 20 min at room temperature in the dark with cocktail of antibodies including anti-CD4-APC, anti-CD25-FITC, anti-FOXP3-PE, anti-PD1-PeCy7, anti-IL10-APC, anti-CD127-APC, anti-CD8PeCy5, anti-NOTCH1 PE, and anti TGF-β APC (BD Pharmingen, CA, USA). After staining, RBCs were lysed using BD FACS lysing solution (BD Pharmingen, San Jose, CA, USA) as per manufacturer’s instructions.
Anti-Notch1 PE antibody (clone mN1A) was procured from eBiosciences, CA, USA; mN1A antibody reacts with the intracellular domain of human Notch1. The mN1A antibody has a low affinity for the full-length (unprocessed or heterodimeric cell surface) forms of Notch1. Therefore, Notch1 expression was considered intracellular not surface expression.
More than 50,000 cells were acquired for flow-cytometric analyses on BD FACS Caliber and the results were analyzed using the TreeStar Flow-Jo software version 8.8.7.
+ Open protocol
+ Expand
10

Isolation of SARS-CoV-2 RBD-specific memory B cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Probe-specific single B cells were sorted as previously described [27 (link)]. Briefly, one tube of PBMCs was thawed in water at 37 °C and resuspended in a prewarmed RPMI-1640 (Corning, Corning, NY, USA) containing 10% fetal bovine serum (Sera Pro, Gremlingen, BW, Germany) and 50 IU/mL benzonase (Sigma, St. Louis, MO, USA). After washing with PBS, the PBMCs were stained with a LIVE/DEAD dye (Invitrogen, Carlsbad, CA, USA) on ice for 20 min. After washing, the PBMCs were stained with an antibody cocktail containing anti-CD3-Pacific Blue, anti-CD8-Pacific Blue, anti-CD19-BV510, anti-IgM-PercpCy5.5, anti-IgG-FITC, anti-CD27-APC-Cy7, anti-PD-1-PECy7, anti-CXCR5-APC-R700, anti-CXCR3-PECy5, anti-CD45RA-BV650, anti-CD4-BV605 (above antibodies are all from BD Biosciences), anti-CD14-eflur450 (ebioscience, USA), anti-CD20-ECD (Beckman Coulter, Bria, CA, USA) and RBD-PE. After filtering through a cell strainer (Corning, Corning, NY, USA), the PBMCs were sorted on BD FACS Aria SORP. RBD-specific single memory B cells were gated as CD3, CD8, DAPI, CD14, CD19+, CD20+, CD27+, IgM, IgG+, RBD-PE+, and were sorted into a 96-well PCR plate containing cell lysis buffer. Then, the PCR plate was frozen immediately at −80 °C and stored overnight.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!